Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluoxetine for Visual Recovery After Ischemic Stroke

Next Previous
Trial Profile

Fluoxetine for Visual Recovery After Ischemic Stroke

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluoxetine (Primary)
  • Indications Vision disorders
  • Focus Therapeutic Use
  • Acronyms FLUORESCE

Most Recent Events

  • 01 Jun 2023 Primary endpoint has not been met (Improvement in size of visual field deficit (degrees)), according to Results published in the Journal of Neuro-Ophthalmology
  • 01 Jun 2023 Results published in the Journal of Neuro-Ophthalmology
  • 20 Aug 2020 According to clinicaltrials.gov the study was discontinued because of slow recruitment and lack of funding to expand to other sites.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top